Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/31/2010CN101687817A Tri-amino-pyrimidine cyclobutenedione derivatives used as phosphatase cdc25 inhibitors
03/31/2010CN101687812A 2 -imidazolines having a good affinity to the trace amine associated receptors (TAAR)
03/31/2010CN101687811A 4-imidazolines and their use as antidepressants
03/31/2010CN101687810A Bicyclic compound and pharmaceutical use thereof
03/31/2010CN101687808A indazolamide derivatives
03/31/2010CN101687807A 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof
03/31/2010CN101687805A Benzazepine derivatives useful as vasopressin antagonists
03/31/2010CN101687802A Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
03/31/2010CN101687800A glucokinase activator
03/31/2010CN101687799A Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
03/31/2010CN101687798A Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
03/31/2010CN101687797A Malonamide derivatives with antithrombotic activity
03/31/2010CN101687795A Neurite formation promoter
03/31/2010CN101687793A Crystal forms of saxagliptin and processes for preparing same
03/31/2010CN101687792A Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
03/31/2010CN101687786A Hydroxylamine compounds and methods of their use
03/31/2010CN101687782A Ion channel modulators and methods of use
03/31/2010CN101687777A Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same
03/31/2010CN101687774A Benzamides useful as s1p receptor modulators
03/31/2010CN101687773A Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
03/31/2010CN101687772A Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same
03/31/2010CN101687758A Substituted biphenyl carboxylic acids and derivatives thereof
03/31/2010CN101687104A Cancer treatment combination therapy comprising vinflunine and trastuzumab
03/31/2010CN101687049A Immunocytokines for cancer treatment in combination with chemotherapeutic agents
03/31/2010CN101687044A Formulations for the oral administration of therapeutic agents and related methods
03/31/2010CN101687043A Coated oral nicotine formulation buffered with amino acid
03/31/2010CN101687042A Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
03/31/2010CN101687041A N-halogenated amino acid formulations with anti-inflammatory compounds
03/31/2010CN101687036A CHK1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
03/31/2010CN101687017A Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
03/31/2010CN101687014A compositions and methods for treating pathologic angiogenesis and vascular permeability
03/31/2010CN101687009A Methods of treatment of skin ulcers
03/31/2010CN101687007A Composition for prevention and/or treatment of peptic ulcer
03/31/2010CN101687005A Methods for treating cancer using agents that inhibit wnt16 signaling
03/31/2010CN101686996A Sulphated xylans for treatment or prophylaxis of respiratory diseases
03/31/2010CN101686995A Modulation of intestinal flora of HIV patients
03/31/2010CN101686994A Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
03/31/2010CN101686991A Compositions useful for reducing nephrotoxicity and methods of use thereof
03/31/2010CN101686990A Antiviral agent
03/31/2010CN101686989A substituted imidazoheterocycles
03/31/2010CN101686988A pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
03/31/2010CN101686987A Treatment of tardive dyskinesia with pyridoxal 5'-phosphate
03/31/2010CN101686986A cyclitols and their derivatives and their therapeutic applications
03/31/2010CN101686985A Cytotoxic t cell activator comprising ep4 agonist
03/31/2010CN101686984A Pharmaceutical combination of nsaid and prostaglandin compound
03/31/2010CN101686983A Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
03/31/2010CN101686982A Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
03/31/2010CN101686981A diazo bicyclic smac mimetics and the uses thereof
03/31/2010CN101686980A Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
03/31/2010CN101686979A Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
03/31/2010CN101686978A Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
03/31/2010CN101686977A Therapeutic or prophylactic agent for dyskinesia
03/31/2010CN101686976A Stable solid preparation comprising 4,5-epoxymorphinan derivative
03/31/2010CN101686975A Antitumour combinations containing a vegf inhibiting agent and irinotecan
03/31/2010CN101686974A Methods for reducing allergies caused by environmental allergens
03/31/2010CN101686973A Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
03/31/2010CN101686972A Therapeutic compositions and the use thereof
03/31/2010CN101686971A Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
03/31/2010CN101686970A Synergistic combination of anthranilamide pyridinureas and benzamide derivatives
03/31/2010CN101686969A crystalline polymorph of exemestane
03/31/2010CN101686968A crystalline polymorph of 7-ethyl-10-hydroxycamptothecin
03/31/2010CN101686967A Pyrazolo pyridine derivatives as nadph oxidase inhibitors
03/31/2010CN101686966A Method of treating cell proliferative disorders using growth hormone secretagogues
03/31/2010CN101686965A Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
03/31/2010CN101686964A Anti-bacterial drug targeting of genome maintenance interfaces
03/31/2010CN101686963A Composition having lipolytic activity, production method thereof and use of the composition
03/31/2010CN101686962A Anthelmintic combination
03/31/2010CN101686961A Transglutaminase inhibitor comprising egcg and a method for producing thereof
03/31/2010CN101686960A Methods and compositions for contributing to the treatment of cancers
03/31/2010CN101686959A Combination therapy with a compound acting as a platelet ADP receptor inhibitor
03/31/2010CN101686958A Topical fungicidal agents for treating nail disorders
03/31/2010CN101686957A Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis
03/31/2010CN101686956A Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins
03/31/2010CN101686955A Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
03/31/2010CN101686954A Inhibition of AGE formation
03/31/2010CN101686953A Use of 4-(nitrooxy)-butyl-(s)-2-(6-methoxy-2-naphtyl)-propanoate for treating pain and inflammation
03/31/2010CN101686952A Novel agents of calcium ion channel modulators
03/31/2010CN101686951A selective proteasome inhibitors for treating diabetes
03/31/2010CN101686948A pharmaceutical cyclosporin compositions
03/31/2010CN101686947A duloxetine formulation
03/31/2010CN101686945A Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
03/31/2010CN101686944A High dose composition of ursodeoxycholic acid
03/31/2010CN101686941A Pharmaceutical solid preparation and production method thereof
03/31/2010CN101686938A Oral pharmaceutical solutions containing telbivudine
03/31/2010CN101686937A Oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder
03/31/2010CN101686936A Use of a natural polysaccharide gel for production of an injectable formulation for treating joint degeneration
03/31/2010CN101686934A Dual portion dosage lozenge form
03/31/2010CN101686922A a liquid formulation for administering nicotine
03/31/2010CN101686919A Use of citrulline for the treatment of conditions linked to an increase in protein carbonylation
03/31/2010CN101686918A Slimming composition
03/31/2010CN101686726A Milk fat-milk protein composition (preferably esterified with palmitic acid) for improving calcium absorption
03/31/2010CN101686725A Synergistic anti-inflammatory and antioxidant dietary supplement compositions
03/31/2010CN101686723A Food composition for prodromal dementia patients
03/31/2010CN101686682A therapeutic pyrazoloquinoline urea derivatives
03/31/2010CN101686681A Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
03/31/2010CN101686680A Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
03/31/2010CN101686676A Methods and compositions of derivatives of probucol for the treatment of diabetes
03/31/2010CN101686675A chemical compounds
03/31/2010CN101686674A isomers of inositol niacinate and uses thereof
03/31/2010CN101686673A Methods for treating neoplasia with combination of chemotherapeutic agents and radiation
1 ... 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 ... 7860